These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21531932)

  • 1. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
    Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
    J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
    Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
    J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
    Ripamonti CI; Maniezzo M; Campa T; Fagnoni E; Brunelli C; Saibene G; Bareggi C; Ascani L; Cislaghi E
    Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
    Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
    Coleman R; Woodward E; Brown J; Cameron D; Bell R; Dodwell D; Keane M; Gil M; Davies C; Burkinshaw R; Houston SJ; Grieve RJ; Barrett-Lee PJ; Thorpe H
    Breast Cancer Res Treat; 2011 Jun; 127(2):429-38. PubMed ID: 21394500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
    Lescaille G; Coudert AE; Baaroun V; Ostertag A; Charpentier E; Javelot MJ; Tolédo R; Goudot P; Azérad J; Berdal A; Spano JP; Ruhin B; Descroix V
    Bone; 2014 Jan; 58():103-7. PubMed ID: 24120382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
    Manfredi M; Mergoni G; Goldoni M; Salvagni S; Merigo E; Meleti M; Vescovi P
    Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e342-e348. PubMed ID: 28390132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
    Saad F; Brown JE; Van Poznak C; Ibrahim T; Stemmer SM; Stopeck AT; Diel IJ; Takahashi S; Shore N; Henry DH; Barrios CH; Facon T; Senecal F; Fizazi K; Zhou L; Daniels A; Carrière P; Dansey R
    Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer.
    Goldman ML; Denduluri N; Berman AW; Sausville R; Guadagnini JP; Kleiner DE; Brahim JS; Swain SM
    Oncology; 2006; 71(3-4):306-8. PubMed ID: 17657174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
    Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
    JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
    BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.